Medulloblastoma: time-dose relationship based on a 30-year review

Area of Science:

• Pediatric Oncology
• Radiation Oncology
• Neuro-oncology

Background:

• Time-dose relationships are critical in cancer treatment.
• Medulloblastoma radiotherapy requires careful consideration of treatment timing.
• A 30-year institutional experience provides a robust dataset for analysis.

Purpose of the Study:

• To evaluate the impact of time factors in postoperative medulloblastoma radiotherapy.
• To identify radiotherapy variables influencing patient outcomes.
• To optimize treatment strategies for medulloblastoma.

Main Methods:

• Retrospective analysis of 53 medulloblastoma patients treated with craniospinal radiotherapy.
• Evaluation of surgical extent, adjuvant chemotherapy, and radiotherapy parameters (dose, fractionation, duration).
• Kaplan-Meier survival and multivariate analyses were performed.

Main Results:

• Overall survival at 5 and 10 years was 68% and 64%; freedom from relapse was 61% and 52%.
• Posterior fossa control rates were significantly influenced by surgical extent and radiotherapy duration.
• Treatment courses ≤45 days showed superior 5-year posterior fossa control (89%) and freedom from relapse (76%) compared to longer courses.

Conclusions:

• Radiotherapy treatment duration is a significant predictor of medulloblastoma control and relapse-free survival.
• Adequate radiation doses combined with shorter treatment durations optimize outcomes.
• Daily fractions of at least 1.75 Gy or twice-daily fractionation are recommended for optimal local control.